JP2024511853A5 - - Google Patents

Info

Publication number
JP2024511853A5
JP2024511853A5 JP2023560403A JP2023560403A JP2024511853A5 JP 2024511853 A5 JP2024511853 A5 JP 2024511853A5 JP 2023560403 A JP2023560403 A JP 2023560403A JP 2023560403 A JP2023560403 A JP 2023560403A JP 2024511853 A5 JP2024511853 A5 JP 2024511853A5
Authority
JP
Japan
Prior art keywords
seq
domain
queel
amino acid
gfral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511853A (ja
Filing date
Publication date
Priority claimed from GBGB2104556.2A external-priority patent/GB202104556D0/en
Priority claimed from GBGB2107331.7A external-priority patent/GB202107331D0/en
Priority claimed from GBGB2108170.8A external-priority patent/GB202108170D0/en
Application filed filed Critical
Priority claimed from PCT/EP2022/058669 external-priority patent/WO2022207846A1/en
Publication of JP2024511853A publication Critical patent/JP2024511853A/ja
Publication of JP2024511853A5 publication Critical patent/JP2024511853A5/ja
Pending legal-status Critical Current

Links

JP2023560403A 2021-03-31 2022-03-31 Gdf15シグナル伝達の治療的阻害剤 Pending JP2024511853A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2104556.2 2021-03-31
GBGB2104556.2A GB202104556D0 (en) 2021-03-31 2021-03-31 Therapeutic inhibitors of GDF15 signalling
GBGB2107331.7A GB202107331D0 (en) 2021-05-21 2021-05-21 Therapeutic inhibitors of GDF15 signalling
GB2107331.7 2021-05-21
GB2108170.8 2021-06-08
GBGB2108170.8A GB202108170D0 (en) 2021-06-08 2021-06-08 Theraputic inhibitors of GDF15 Signalling
PCT/EP2022/058669 WO2022207846A1 (en) 2021-03-31 2022-03-31 Therapeutic inhibitors of gdf15 signalling

Publications (2)

Publication Number Publication Date
JP2024511853A JP2024511853A (ja) 2024-03-15
JP2024511853A5 true JP2024511853A5 (cg-RX-API-DMAC7.html) 2025-04-07

Family

ID=81580347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560403A Pending JP2024511853A (ja) 2021-03-31 2022-03-31 Gdf15シグナル伝達の治療的阻害剤

Country Status (11)

Country Link
US (1) US20240182585A1 (cg-RX-API-DMAC7.html)
EP (1) EP4314071A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024511853A (cg-RX-API-DMAC7.html)
KR (1) KR20230165285A (cg-RX-API-DMAC7.html)
AU (1) AU2022251923A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020152A2 (cg-RX-API-DMAC7.html)
CA (1) CA3215737A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023013791A2 (cg-RX-API-DMAC7.html)
IL (1) IL307382A (cg-RX-API-DMAC7.html)
MX (1) MX2023011655A (cg-RX-API-DMAC7.html)
WO (1) WO2022207846A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117986363A (zh) 2016-03-31 2024-05-07 恩格姆生物制药公司 结合蛋白及其使用方法
JP2026505740A (ja) * 2023-01-20 2026-02-18 コリア アドバンスト インスティチュート オブ サイエンス アンド テクノロジー Gfralを標的にするアンチセンスオリゴマー及びこの用途
IT202300006387A1 (it) * 2023-03-31 2024-10-01 Univ Degli Studi Roma La Sapienza Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
DK2441466T3 (da) 2004-04-13 2014-10-27 St Vincents Hosp Sydney MIC-1-inhiberende middel
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2011070177A2 (en) 2009-12-11 2011-06-16 Baltic Technology Development, Ltd. Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators
WO2013012648A1 (en) 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
AU2013322628B2 (en) 2012-09-26 2017-03-02 Julius-Maximilians-Universitat Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15)
ES3066738T3 (en) 2012-12-21 2026-05-14 Aveo Pharmaceuticals Inc Anti-gdf15 antibodies
PT3653644T (pt) 2014-03-26 2023-12-19 Univ Wuerzburg J Maximilians Anticorpos monoclonais do fator de crescimento e diferenciação 15 (gdf-15) e suas utilizações para o tratamento da caquexia cancerosa e do cancro
EP3851122A1 (en) 2014-09-25 2021-07-21 Aveo Pharmaceuticals Inc. Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
KR102722730B1 (ko) 2015-10-02 2024-10-25 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 인간 증식 및 분화 인자 15 (gdf-15)의 저해제와 면역 체크포인트 차단제를 이용한 병용 요법
WO2017121865A1 (en) 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof
JP2019510739A (ja) * 2016-02-29 2019-04-18 イーライ リリー アンド カンパニー Gfral受容体療法
AU2017228489A1 (en) * 2016-03-04 2018-09-06 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
CN117986363A (zh) 2016-03-31 2024-05-07 恩格姆生物制药公司 结合蛋白及其使用方法
JP7138567B2 (ja) 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子15に対する抗体およびそれらの使用

Similar Documents

Publication Publication Date Title
JP7665098B2 (ja) 多重特異性抗体およびその使用
JP7682335B2 (ja) オンコスタチンm受容体抗原結合タンパク質
US12194095B2 (en) Combinations and uses thereof
KR102500868B1 (ko) 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도
JP2018521691A5 (cg-RX-API-DMAC7.html)
BR112021008288A2 (pt) composição farmacêutica de proteína de fusão do receptor tgf-ss e uso da mesma
RU2019139093A (ru) Фармацевтическая композиция на основе антитела к pd-l1 и ее применение
RU2018106364A (ru) Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств
JP2016538876A5 (cg-RX-API-DMAC7.html)
RU2014139552A (ru) Человеческие антитела к токсинам clostridium difficile
KR20160062167A (ko) 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도
JP2015503909A5 (cg-RX-API-DMAC7.html)
WO2012098238A1 (en) Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
KR20160135835A (ko) 인간 카나비노이드 1(cb1) 수용체 결합 항체
JP2020522280A5 (cg-RX-API-DMAC7.html)
JP2022544050A5 (cg-RX-API-DMAC7.html)
TW202108631A (zh) 一種抗cd47抗原結合蛋白及其應用
JP2022527542A5 (cg-RX-API-DMAC7.html)
JP2024505195A5 (cg-RX-API-DMAC7.html)
JP2024502670A5 (cg-RX-API-DMAC7.html)
JP2022537142A5 (cg-RX-API-DMAC7.html)
JP7668943B2 (ja) 多重特異性抗体およびその使用
CN114316046B (zh) 一种稳定的抗体组合物
JP2025539796A (ja) Lag-3およびpd-1/lag-3抗体
AU2023355736A1 (en) Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer